Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 6,556 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,556 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $180,158.88. Following the completion of the sale, the general counsel now directly owns 152,361 shares of the company’s stock, valued at approximately $4,186,880.28. This trade represents a 4.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Phreesia Stock Performance

Shares of PHR stock opened at $28.81 on Thursday. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.90. The company’s fifty day simple moving average is $24.57 and its 200-day simple moving average is $23.20. The firm has a market cap of $1.67 billion, a PE ratio of -19.60 and a beta of 0.94. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.58) EPS. Equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. R Squared Ltd bought a new position in shares of Phreesia in the fourth quarter valued at $30,000. International Assets Investment Management LLC grew its position in shares of Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares during the period. XTX Topco Ltd acquired a new position in shares of Phreesia during the 3rd quarter worth about $247,000. Hsbc Holdings PLC bought a new stake in shares of Phreesia in the 2nd quarter valued at about $301,000. Finally, Intech Investment Management LLC acquired a new stake in Phreesia in the 3rd quarter valued at about $316,000. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PHR has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Truist Financial upped their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Citigroup boosted their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler reaffirmed an “overweight” rating and set a $33.00 price target (up previously from $31.00) on shares of Phreesia in a research report on Wednesday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia currently has an average rating of “Buy” and a consensus price target of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.